SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Jyong Biotech Ltd.
Date: June 12, 2025 · CIK: 0001954488 · Accession: 0001213900-25-053881

Offering / Registration Process Regulatory Compliance Business Model Clarity

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-277725

Date
June 12, 2025
Author
Joseph Stone Capital, LLC
Form
CORRESP
Company
Jyong Biotech Ltd.

Letter

Joseph Stone Capital, LLC

Via EDGAR

June 12, 2025

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, D.C., 20549

Attention: Doris Stacey

Suzanne Hayes Ibolya Ignat Mary Mast

Re: Jyong Biotech Ltd.

Registration Statement on Form F-1, as amended

Initially Filed on March 7, 2024

File No. 333-277725

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Joseph Stone Capital, LLC, as the representative of underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on June 16, 2025 , or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act, we wish to advise you that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.

We have been advised by the prospective underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
Joseph Stone Capital, LLC

Show Raw Text
CORRESP
 1
 filename1.htm

 Joseph Stone Capital, LLC

 Via EDGAR

 June 12, 2025

 Division of Corporation Finance

 Office of Life Sciences

 U.S. Securities and Exchange Commission

 100 F Street, NE

 Washington, D.C., 20549

 Attention:
 Doris Stacey

 Suzanne Hayes
 Ibolya Ignat
 Mary Mast

 Re:
 Jyong Biotech Ltd.

 Registration Statement on Form F-1, as amended

 Initially Filed on March 7, 2024

 File No. 333-277725

 Ladies and Gentlemen:

 Pursuant
to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended,
Joseph Stone Capital, LLC, as the representative of underwriters, hereby requests acceleration of the effective date of the above-referenced
Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on June
16, 2025 , or as soon thereafter as practicable.

 Pursuant
to Rule 460 under the Securities Act, we wish to advise you that we will take reasonable steps to secure adequate distribution of the
preliminary prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.

 We have been advised
by the prospective underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 under
the Securities Exchange Act of 1934, as amended.

 Very truly yours,

 Joseph Stone Capital, LLC

 By:
 /s/Damian Maggio

 Name:
 Damian Maggio

 Title:
 Chief Executive Officer